Issue Date: February 13, 2006
Strategies Shift In Contract Biologics
When DSM revealed in late December that it was planning to mothball its biologics facility in Montreal and shift its biopharmaceutical focus away from commercial manufacturing "hardware" to technological "software," the announcement had a familiar ring. Dow Chemical's Dowpharma business unit had made a similar move a year earlier, emphasizing development of its Pseudomonas-based Pfenex technology for producing biopharmaceuticals over its previous commercial-scale contract manufacturing plans.
Both companies' decisions were made in the . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society